2.7.1.154 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11714830&form=6&db=m Involvement of phosphoinositide 3-kinases in neutrophil activation and the development of acute lung injury. causal interaction,unassigned 3,0 2.7.1.154 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24244039&form=6&db=m Novel phosphoinositide 3-kinase ?,? inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis. causal interaction,ongoing research,therapeutic application,unassigned 2,3,4,0 2.7.1.154 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24262886&form=6&db=m Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase ? inhibitor for the treatment of inflammatory diseases. causal interaction,therapeutic application,unassigned 4,4,0 2.7.1.154 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20148286&form=6&db=m Consensus model for identification of novel PI3K inhibitors in large chemical library. causal interaction,therapeutic application,unassigned 4,4,0 2.7.1.154 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20351038&form=6&db=m Phosphoinositide 3-kinase {delta} inhibitor suppresses IL-17 expression in a murine asthma model. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 2.7.1.154 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27556731&form=6&db=m Comprehensive attenuation of IL-25-induced airway hyperresponsiveness, inflammation and remodelling by the PI3K inhibitor LY294002. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 2.7.1.154 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29651336&form=6&db=m PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,4,2 2.7.1.154 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16789742&form=6&db=m Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. causal interaction,therapeutic application,unassigned 2,3,0 2.7.1.154 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19689378&form=6&db=m Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma. causal interaction,therapeutic application,unassigned 4,4,0 2.7.1.154 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24735732&form=6&db=m PI3K inhibitors as potential therapeutics for autoimmune disease. causal interaction,therapeutic application,unassigned 4,4,0 2.7.1.154 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22586300&form=6&db=m GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.7.1.154 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22744290&form=6&db=m PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. unassigned - 2.7.1.154 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25368680&form=6&db=m Amplification of Chromosome 1q Genes Encoding the Phosphoinositide Signalling Enzymes PI4KB, AKT3, PIP5K1A and PI3KC2B in Breast Cancer. causal interaction,unassigned 3,0 2.7.1.154 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26934321&form=6&db=m Class II phosphoinositide 3-kinase C2? regulates a novel signaling pathway involved in breast cancer progression. causal interaction,therapeutic application,unassigned 4,2,0 2.7.1.154 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33783250&form=6&db=m Identification and Kinetic Characterization of Serum- and Glucocorticoid-Regulated Kinase Inhibitors Using a Fluorescence Polarization-Based Assay. causal interaction,diagnostic usage,unassigned 2,2,0 2.7.1.154 Burkitt Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26561567&form=6&db=m Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 2.7.1.154 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11552264&form=6&db=m [Involvement of phosphoinositide 3-kinases and phosphoinositide phosphatases in immune responses, glucose metabolism and tumorigenesis] unassigned - 2.7.1.154 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18043260&form=6&db=m Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.7.1.154 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18270679&form=6&db=m Activation of phosphoinositide 3-kinase by the NBS1 DNA repair protein through a novel activation motif. causal interaction,therapeutic application,unassigned 4,4,0 2.7.1.154 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25622909&form=6&db=m Phosphatidylinositol 3-kinase, class 2 beta (PI3KC2?) isoform contributes to neuroblastoma tumorigenesis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,3 2.7.1.154 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31985569&form=6&db=m The recent progress and therapy in endometriosis-associated ovarian cancer. causal interaction,ongoing research,unassigned 2,2,0 2.7.1.154 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33783250&form=6&db=m Identification and Kinetic Characterization of Serum- and Glucocorticoid-Regulated Kinase Inhibitors Using a Fluorescence Polarization-Based Assay. causal interaction,diagnostic usage,unassigned 2,2,0 2.7.1.154 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31985569&form=6&db=m The recent progress and therapy in endometriosis-associated ovarian cancer. causal interaction,ongoing research,unassigned 2,2,0 2.7.1.154 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11424083&form=6&db=m beta-estradiol stimulation of DNA synthesis requires different PKC isoforms in HepG2 and MCF7 cells. therapeutic application,unassigned 1,0 2.7.1.154 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24055031&form=6&db=m A class II phosphoinositide 3-kinase plays an indispensable role in hepatitis C virus replication. causal interaction,ongoing research,unassigned 4,4,0 2.7.1.154 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16775008&form=6&db=m Phosphoinositide 3-Kinase C2beta Regulates Cytoskeletal Organization and Cell Migration via Rac-dependent Mechanisms. causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 2.7.1.154 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16127437&form=6&db=m Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 2.7.1.154 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20148286&form=6&db=m Consensus model for identification of novel PI3K inhibitors in large chemical library. causal interaction,therapeutic application,unassigned 4,4,0 2.7.1.154 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20626398&form=6&db=m PI3K Inhibitors in Cardiovascular Disease. causal interaction,therapeutic application,unassigned 4,4,0 2.7.1.154 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21568907&form=6&db=m Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors. causal interaction,unassigned 1,0 2.7.1.154 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21649578&form=6&db=m Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. causal interaction,unassigned 1,0 2.7.1.154 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22528234&form=6&db=m Down-regulation of p110? expression increases chemosensitivity of colon cancer cell lines to oxaliplatin. ongoing research,therapeutic application,unassigned 3,4,0 2.7.1.154 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25785104&form=6&db=m PIK3C2G copy number is associated with clinical outcomes of colorectal cancer patients treated with oxaliplatin. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 2.7.1.154 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33783250&form=6&db=m Identification and Kinetic Characterization of Serum- and Glucocorticoid-Regulated Kinase Inhibitors Using a Fluorescence Polarization-Based Assay. causal interaction,diagnostic usage,unassigned 2,2,0 2.7.1.154 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17991425&form=6&db=m Association of the PIK3C2G gene polymorphisms with type 2 DM in a Japanese population. diagnostic usage,ongoing research,unassigned 1,3,0 2.7.1.154 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20061534&form=6&db=m Insulin-feedback via PI3K-C2{alpha} activated PKB{alpha}/Akt1 is required for glucose-stimulated insulin secretion. causal interaction,therapeutic application,unassigned 3,3,0 2.7.1.154 Diabetic Cardiomyopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29215436&form=6&db=m Phosphoinositide 3-kinases and Diabetic Cardiomyopathy. causal interaction,unassigned 3,0 2.7.1.154 Diphtheria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21081650&form=6&db=m PI3KC2?, a class II PI3K, is required for dynamin-independent internalization pathways. unassigned - 2.7.1.154 Encephalomyelitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34445401&form=6&db=m PI3-Kinase p110? Deficiency Modulates T Cell Homeostasis and Function and Attenuates Experimental Allergic Encephalitis in Mature Mice. ongoing research,therapeutic application,unassigned 3,2,0 2.7.1.154 Encephalomyelitis, Autoimmune, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34445401&form=6&db=m PI3-Kinase p110? Deficiency Modulates T Cell Homeostasis and Function and Attenuates Experimental Allergic Encephalitis in Mature Mice. ongoing research,therapeutic application,unassigned 3,2,0 2.7.1.154 Epilepsy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24219064&form=6&db=m Phosphoinositide 3-Kinases Upregulate System xc(-) via Eukaryotic Initiation Factor 2? and Activating Transcription Factor 4?-?A Pathway Active in Glioblastomas and Epilepsy. diagnostic usage,ongoing research,unassigned 1,3,0 2.7.1.154 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17611681&form=6&db=m 3-Methyladenine suppresses cell migration and invasion of HT1080 fibrosarcoma cells through inhibiting phosphoinositide 3-kinases independently of autophagy inhibition. causal interaction,ongoing research,therapeutic application,unassigned 2,1,1,0 2.7.1.154 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24219064&form=6&db=m Phosphoinositide 3-Kinases Upregulate System xc(-) via Eukaryotic Initiation Factor 2? and Activating Transcription Factor 4?-?A Pathway Active in Glioblastomas and Epilepsy. diagnostic usage,ongoing research,unassigned 1,3,0 2.7.1.154 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33783250&form=6&db=m Identification and Kinetic Characterization of Serum- and Glucocorticoid-Regulated Kinase Inhibitors Using a Fluorescence Polarization-Based Assay. causal interaction,diagnostic usage,unassigned 2,2,0 2.7.1.154 Hepatitis C http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24055031&form=6&db=m A class II phosphoinositide 3-kinase plays an indispensable role in hepatitis C virus replication. causal interaction,ongoing research,unassigned 4,4,0 2.7.1.154 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16336212&form=6&db=m Class II phosphoinositide 3-kinase alpha-isoform regulates Rho, myosin phosphatase and contraction in vascular smooth muscle. therapeutic application,unassigned 2,0 2.7.1.154 Immune System Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24095650&form=6&db=m Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 2.7.1.154 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29733959&form=6&db=m iTRAQ-based proteomic profile analysis of ISKNV-infected CPB cells with emphasizing on glucose metabolism, apoptosis and autophagy pathways. causal interaction,ongoing research,therapeutic application,unassigned 2,2,1,0 2.7.1.154 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23010262&form=6&db=m Discovery of phosphoinositide 3-kinases (PI3K) p110? isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance. causal interaction,therapeutic application,unassigned 2,4,0 2.7.1.154 Insulinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21127054&form=6&db=m Class II phosphoinositide 3-kinase regulates exocytosis of insulin granules in pancreatic beta cells. ongoing research,unassigned 4,0 2.7.1.154 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19176369&form=6&db=m Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,1,4 2.7.1.154 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23086418&form=6&db=m Class I phosphoinositide 3-kinases in normal and pathologic hematopoietic cells. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 2.7.1.154 Leukemia, Lymphocytic, Chronic, B-Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26338274&form=6&db=m The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. causal interaction,unassigned 4,0 2.7.1.154 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23086418&form=6&db=m Class I phosphoinositide 3-kinases in normal and pathologic hematopoietic cells. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 2.7.1.154 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19176369&form=6&db=m Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,1,4 2.7.1.154 Lymphadenopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27221134&form=6&db=m Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase ? syndrome 2: A cohort study. unassigned - 2.7.1.154 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16619289&form=6&db=m Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. ongoing research,therapeutic application,unassigned 1,2,0 2.7.1.154 Lymphoma, Follicular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26997445&form=6&db=m miR-31 and miR-17-5p levels change during transformation of follicular lymphoma. causal interaction,therapeutic application,unassigned 4,1,0 2.7.1.154 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33663586&form=6&db=m Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma. ongoing research,unassigned 2,0 2.7.1.154 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34445401&form=6&db=m PI3-Kinase p110? Deficiency Modulates T Cell Homeostasis and Function and Attenuates Experimental Allergic Encephalitis in Mature Mice. ongoing research,therapeutic application,unassigned 3,2,0 2.7.1.154 Myopathies, Structural, Congenital http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30451843&form=6&db=m Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy. causal interaction,diagnostic usage,unassigned 4,3,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11687500&form=6&db=m Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. causal interaction,therapeutic application,unassigned 3,3,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15017460&form=6&db=m Signal Transduction Pathways as Therapeutic Targets. 25-28 January 2004, Luxembourg. causal interaction,therapeutic application,unassigned 4,1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15932879&form=6&db=m Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. diagnostic usage,ongoing research,unassigned 3,1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15963759&form=6&db=m Phosphoinositide 3-kinases as drug targets in cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16127437&form=6&db=m Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16274621&form=6&db=m The Essential Role of Phosphoinositide 3-Kinases (PI3Ks) in Regulating Pro-Inflammatory Responses and the Progression of Cancer. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16775008&form=6&db=m Phosphoinositide 3-Kinase C2beta Regulates Cytoskeletal Organization and Cell Migration via Rac-dependent Mechanisms. causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18043260&form=6&db=m Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18403640&form=6&db=m Down-regulation of class II phosphoinositide 3-kinase alpha expression below a critical threshold induces apoptotic cell death. causal interaction,therapeutic application,unassigned 1,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18837901&form=6&db=m The transforming functions of PI3-kinase-gamma are linked to disruption of intercellular adhesion and promotion of cancer cell invasion. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19318683&form=6&db=m Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. causal interaction,therapeutic application,unassigned 4,3,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19690175&form=6&db=m Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19840522&form=6&db=m Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions. causal interaction,unassigned 4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20148286&form=6&db=m Consensus model for identification of novel PI3K inhibitors in large chemical library. causal interaction,therapeutic application,unassigned 4,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20224967&form=6&db=m Targeting PI3K in neuroblastoma. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21568907&form=6&db=m Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors. causal interaction,unassigned 1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21568908&form=6&db=m Present and Future of PI3K Pathway Inhibition in Cancer: Perspectives and Limitations. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21643420&form=6&db=m Characterisation of the PTEN inhibitor VO-OHpic. causal interaction,therapeutic application,unassigned 1,3,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21649577&form=6&db=m Present and future of PI3K pathway inhibition in cancer: perspectives and limitations. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21649578&form=6&db=m Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. causal interaction,unassigned 1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21893353&form=6&db=m Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,3,1 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21930956&form=6&db=m Calpain interacts with class IA phosphoinositide 3-kinases regulating their stability and signaling activity. causal interaction,unassigned 3,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22120714&form=6&db=m Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases. causal interaction,unassigned 4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22814170&form=6&db=m Different PI 3-kinase inhibitors have distinct effects on endothelial permeability and leukocyte transmigration. causal interaction,unassigned 3,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23016860&form=6&db=m Genetic and epigenetic regulation of phosphoinositide 3-kinase Isoforms. therapeutic application,unassigned 1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23086418&form=6&db=m Class I phosphoinositide 3-kinases in normal and pathologic hematopoietic cells. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23265896&form=6&db=m Regioselective synthesis of 5- and 6-methoxybenzimidazole-1,3,5-triazines as inhibitors of phosphoinositide 3-kinase. causal interaction,therapeutic application,unassigned 4,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23837532&form=6&db=m Extended treatment with selective PI 3-kinase and mTOR inhibitors has effects on metabolism, growth, behaviour and bone strength. ongoing research,unassigned 1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24095650&form=6&db=m Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24195664&form=6&db=m Recent Developments of Small Molecule PI3K/mTOR Dual Inhibitors. causal interaction,unassigned 4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24897931&form=6&db=m PI3K/AKT signaling pathway and cancer: an updated review. therapeutic application,unassigned 1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24915189&form=6&db=m Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. causal interaction,therapeutic application,unassigned 3,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25047838&form=6&db=m Uncovering the PI3Ksome: phosphoinositide 3-kinases and counteracting PTEN form a signaling complex with intrinsic regulatory properties. unassigned - 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25317974&form=6&db=m Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602. ongoing research,unassigned 1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25360116&form=6&db=m Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts. causal interaction,diagnostic usage,unassigned 4,1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25550888&form=6&db=m PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25727005&form=6&db=m TSC1 Activates TGF-?-Smad2/3 Signaling in Growth Arrest and Epithelial-to-Mesenchymal Transition. causal interaction,therapeutic application,unassigned 3,1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26883061&form=6&db=m ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis. causal interaction,therapeutic application,unassigned 1,2,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26934321&form=6&db=m Class II phosphoinositide 3-kinase C2? regulates a novel signaling pathway involved in breast cancer progression. causal interaction,therapeutic application,unassigned 4,2,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27038473&form=6&db=m Multi-kinase inhibitors, AURKs and cancer. causal interaction,therapeutic application,unassigned 4,1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27308431&form=6&db=m PI3K at the crossroads of tumor angiogenesis signaling pathways. causal interaction,unassigned 2,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27980108&form=6&db=m Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28273837&form=6&db=m Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment. causal interaction,therapeutic application,unassigned 4,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28743532&form=6&db=m A synthetic peptide hijacks the catalytic subunit of class I PI3K to suppress the growth of cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,4 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29868934&form=6&db=m The lipid products of phosphoinositide 3-kinase isoforms in cancer and thrombosis. diagnostic usage,therapeutic application,unassigned 1,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30347774&form=6&db=m Whole Genome Resequencing of Arkansas Progressor and Regressor Line Chickens to Identify SNPs Associated with Tumor Regression. causal interaction,unassigned 4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30591513&form=6&db=m A high-avidity biosensor reveals plasma membrane PI(3,4)P2 is predominantly a class I PI3K signaling product. unassigned - 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30849534&form=6&db=m The relation between PI3K/AKT signalling pathway and cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31176568&form=6&db=m Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31338599&form=6&db=m Theoretical studies on the selectivity mechanisms of PI3K? inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation. diagnostic usage,unassigned 1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31632439&form=6&db=m A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients With GBM. causal interaction,unassigned 3,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31638167&form=6&db=m Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,3 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31752944&form=6&db=m Downregulation of class II phosphoinositide 3-kinase PI3K-C2? delays cell division and potentiates the effect of docetaxel on cancer cell growth. diagnostic usage,ongoing research,unassigned 4,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31831213&form=6&db=m Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases. unassigned - 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31936288&form=6&db=m Phytochemicals and Gastrointestinal Cancer: Cellular Mechanisms and Effects to Change Cancer Progression. ongoing research,therapeutic application,unassigned 3,1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31941829&form=6&db=m Stromal cell protein kinase C-? inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance. ongoing research,unassigned 3,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33491755&form=6&db=m Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33661099&form=6&db=m Disease-related mutations in PI3K? disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors. causal interaction,therapeutic application,unassigned 4,1,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33782397&form=6&db=m Germline mutations in apoptosis pathway genes in ovarian cancer; the functional role of a TP53I3 (PIG3) variant in ROS production and DNA repair. causal interaction,diagnostic usage,unassigned 1,3,0 2.7.1.154 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33783250&form=6&db=m Identification and Kinetic Characterization of Serum- and Glucocorticoid-Regulated Kinase Inhibitors Using a Fluorescence Polarization-Based Assay. causal interaction,diagnostic usage,unassigned 2,2,0 2.7.1.154 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20224967&form=6&db=m Targeting PI3K in neuroblastoma. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,4,0 2.7.1.154 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25622909&form=6&db=m Phosphatidylinositol 3-kinase, class 2 beta (PI3KC2?) isoform contributes to neuroblastoma tumorigenesis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,3 2.7.1.154 Primary Immunodeficiency Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28167755&form=6&db=m Conformational disruption of PI3K? regulation by immunodeficiency mutations in PIK3CD and PIK3R1. unassigned - 2.7.1.154 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26983806&form=6&db=m Novel roles for class II Phosphoinositide 3-Kinase C2? in signalling pathways involved in prostate cancer cell invasion. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 2.7.1.154 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31752944&form=6&db=m Downregulation of class II phosphoinositide 3-kinase PI3K-C2? delays cell division and potentiates the effect of docetaxel on cancer cell growth. diagnostic usage,ongoing research,unassigned 4,4,0 2.7.1.154 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33783250&form=6&db=m Identification and Kinetic Characterization of Serum- and Glucocorticoid-Regulated Kinase Inhibitors Using a Fluorescence Polarization-Based Assay. causal interaction,diagnostic usage,unassigned 2,2,0 2.7.1.154 Psoriasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32585606&form=6&db=m Hypoxia-inducible factor-1: A potential pharmacological target to manage psoriasis. causal interaction,unassigned 1,0 2.7.1.154 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29764505&form=6&db=m Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance. causal interaction,therapeutic application,unassigned 4,2,0 2.7.1.154 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32520634&form=6&db=m The landscape of gene mutations and clinical significance of tumor mutation burden in patients with soft tissue sarcoma who underwent surgical resection and received conventional adjuvant therapy. diagnostic usage,unassigned 4,0 2.7.1.154 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26771196&form=6&db=m In Search of a Cure for Sepsis: Taming the Monster in Critical Care Medicine. causal interaction,ongoing research,unassigned 1,1,0 2.7.1.154 Squamous Cell Carcinoma of Head and Neck http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33476088&form=6&db=m The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 2.7.1.154 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11511514&form=6&db=m Resistance to thromboembolism in PI3Kgamma-deficient mice. therapeutic application,unassigned 1,0 2.7.1.154 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26316615&form=6&db=m Membrane grease eases platelet maturation. causal interaction,ongoing research,therapeutic application,unassigned 2,2,2,0 2.7.1.154 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29868934&form=6&db=m The lipid products of phosphoinositide 3-kinase isoforms in cancer and thrombosis. diagnostic usage,therapeutic application,unassigned 1,4,0 2.7.1.154 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33242335&form=6&db=m Phosphoinositide 3-kinases in platelets, thrombosis and therapeutics. causal interaction,therapeutic application,unassigned 1,2,0 2.7.1.154 Uterine Cervical Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31752944&form=6&db=m Downregulation of class II phosphoinositide 3-kinase PI3K-C2? delays cell division and potentiates the effect of docetaxel on cancer cell growth. diagnostic usage,ongoing research,unassigned 4,4,0 2.7.1.154 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9748276&form=6&db=m The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2alpha. unassigned -